Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: Prerequisite in human melanoma cell invasion

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8924-8931

  Schnaeker, Eva Maria ^a   Ossig, Rainer ^a   Ludwig, Thomas ^a   Dreier, Rita ^a   Oberleithner, Hans ^a   Wilhelmi, M ^a   Schneider, Stefan W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; PACLITAXEL; PROTEINASE;

ANTIBODY LABELING; ARTICLE; CANCER INVASION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MELANOMA CELL; MICROTUBULE; PRIORITY JOURNAL;

ANIMALS; CYTOPLASMIC VESICLES; DOGS; EXOCYTOSIS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, AMELANOTIC; MICROTUBULES; NEOPLASM INVASIVENESS; PACLITAXEL; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED;

EID: 10844266658     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0324     Document Type: Article

References (56)

1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Cire Res 2003;92:827-39.
2. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 2003;384:863-72.
3. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
5. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-74.
6. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
7. Nagase H, Woessner JFJ. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
8. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Investig Dermatol 2000;115:337-44.
9. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
10. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998;58:3743-50.
11. Ahmad A, Hart IR. Mechanisms of metastasis. Crit Rev Oncol Hematol 1997;26:163-73.
12. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33.
13. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-92.
14. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001;61:6322-7.
15. Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, Van Muijen GN. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Investig Dermatol 2000;115:625-32.
16. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
17. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-93.
18. Deryugina EI, Ratnikov B, Monosov E, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001;263:209-23.
19. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000;275:26411-5.
20. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331-8.
21. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
22. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
23. Zak J, Schneider SW, Eue I, Ludwig T, Oberleithner H. High-resistance MDCK-C7 monolayers used for measuring invasive potency of tumour cells. Pflügers Arch 2000;440:179-83.
24. Cunningham CC, Gorlin JB, Kwiatkowski DJ, et al. Actin-binding protein requirement for cortical stability and efficient locomotion. Science 1992;255:325-7.
25. Gekle M, Wunsch S, Oberleithner H, Silbernagl S. Characterization of two MDCK-cell subtypes as a model system to study principal cell and intercalated cell properties. Pflugers Arch 1994;428:157-62.
26. Hachiya NS, Watanabe K, Yamada M, Sakasegawa Y, Kaneko K. Anterograde and retrograde intracellular trafficking of fluorescent cellular prion protein. Biochem Biophys Res Commun 2004;315:802-7.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 1970;227:680-5.
28. Ossig R, Laufer W, Schmitt HD, Gallwitz D. Functionality and specific membrane localization of transport GTPases carrying C-terminal membrane anchors of synaptobrevin-like proteins. EMBO J 1995;14:3645-53.
29. Dreier R, Wallace S, Fuchs S, Bruckner P, Grassel S. Paracrine interactions of chondrocytes and macrophages in cartilage degradation: articular chondrocytes provide factors that activate macrophage-derived pro-gelatinase B (pro-MMP-9). J Cell Sci 2001;114:3813-22.
30. Goerge T, Niemeyer A, Rogge P, Ossig R, Oberleithner H, Schneider SW. Secretion pores in human endothelial cells during acute hypoxia. J Membr Biol 2002;187:203-11.
31. Ludwig T, Ossig R, Graessel S, Wilhelmi M, Oberleithner H, Schneider SW. The electrical resistance breakdown assay determines the role of proteinases in tumor cell invasion. Am J Physiol Renal Physiol 2002;283:F319-27.
32. Sheetz MP. Motor and cargo interactions. Eur J Biochem 1999;262:19-25.
33. Parekh H, Simpkins H. The transport and binding of Taxol. Gen Pharmacol 1997;29:167-72.
34. Jordan MA, Toso RJ. Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-6.
35. Parekh H, Simpkins H. Species-specific differences in Taxol transport and cytotoxicity against human and rodent tumor cells: evidence for an alternate transport system. Biochem Pharmacol 1996;51:301-11.
36. Schliwa M, Woehlke G. Molecular motors. Nature (Lond) 2003;422:759-65.
37. McNiven MA, Marlowe KJ. Contributions of molecular motor enzymes to vesicle-based protein transport in gastrointestinal epithelial cells. Gastroenterology 1999;116:438-51.
38. Kreitzer G, Marmorstein A, Okamoto P, Vallee R, Rodriguez-Boulan E. Kinesin and dynamin are required for post-Golgi transport of a plasma-membrane protein. Nat Cell Biol 2000;2:125-7.
39. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96.
40. Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG. Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep 2002;9:89-92.
41. Romanini A, Tanganelli L, Carnino F, et al. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. Gynecol Oncol 2003;89:354-9.
42. Von Moos R, Thurlimann B. Weekly paclitaxel [Taxol(R)] with or without trastuzumab [Herceptin(R)] in advanced breast cancer: a community-based observation study. Onkologie 2003;26:128-32.
43. Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992;52:3776-81.
44. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1-19.
45. Stearns ME, Wang M. Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of Taxol. Oncol Res 1994;6:195-201.
46. Westerlund A, Hujanen E, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T. Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metastasis 1997;15:318-28.
47. Loennechen T, Mathisen B, Hansen J, et al. Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner. Biochem Pharmacol 2003;66:2341-2353.
48. Oberleithner H, Schneider SW, Albermann L, et al. Endothelial cell swelling by aldosterone. J Membr Biol 2003;196:163-72.
49. Yoshida D, Piepmeier JM, Bergenheim T, Henriksson R, Teramoto A. Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma ceils by anti-microtubule agent: in vitro study. Br J Cancer 1998;77:21-5.
50. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3;193-203.
51. Smith AJ, Pfeiffer JR, Zhang J, Martinez AM, Griffiths GM, Wilson BS. Microtubule-dependent transport of secretory vesicles in RBL-2H3 cells. Traffic 2003;4:302-12.
52. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, Van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MTI-MMP) correlate with melanoma progression. J Pathol 2000;191:245-56.
53. Stearns ME, Wang M. Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines. Cancer Res 1991;51:5866-75.
54. Schneider SW. Kiss and run mechanism in exocytosis. J Membr Biol 2001;181:67-76.
55. Jahn R, Lang T, Sudhof TC. Membrane fusion. Cell 2 2003;112:519-33.
56. Ayala I, Babia T, Baldassarre M, et al. Morphological and biochemical analysis of the secretory pathway in melanoma cells with distinct metastatic potential. FEBS Lett 1999;451:315-20.